144 related articles for article (PubMed ID: 29236331)
21. Association of NDRG1 gene promoter methylation with reduced NDRG1 expression in gastric cancer cells and tissue specimens.
Chang X; Zhang S; Ma J; Li Z; Zhi Y; Chen J; Lu Y; Dai D
Cell Biochem Biophys; 2013 May; 66(1):93-101. PubMed ID: 23099645
[TBL] [Abstract][Full Text] [Related]
22. LSD1 mediates MYCN control of epithelial-mesenchymal transition through silencing of metastatic suppressor NDRG1 gene.
Ambrosio S; Amente S; Saccà CD; Capasso M; Calogero RA; Lania L; Majello B
Oncotarget; 2017 Jan; 8(3):3854-3869. PubMed ID: 27894074
[TBL] [Abstract][Full Text] [Related]
23. Valproic acid induces neuroendocrine differentiation and UGT2B7 up-regulation in human prostate carcinoma cell line.
Valentini A; Biancolella M; Amati F; Gravina P; Miano R; Chillemi G; Farcomeni A; Bueno S; Vespasiani G; Desideri A; Federici G; Novelli G; Bernardini S
Drug Metab Dispos; 2007 Jun; 35(6):968-72. PubMed ID: 17371798
[TBL] [Abstract][Full Text] [Related]
24. Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells.
Yuan TC; Veeramani S; Lin FF; Kondrikou D; Zelivianski S; Igawa T; Karan D; Batra SK; Lin MF
Endocr Relat Cancer; 2006 Mar; 13(1):151-67. PubMed ID: 16601285
[TBL] [Abstract][Full Text] [Related]
25. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression.
Cox ME; Deeble PD; Lakhani S; Parsons SJ
Cancer Res; 1999 Aug; 59(15):3821-30. PubMed ID: 10447001
[TBL] [Abstract][Full Text] [Related]
26. Adiponectin as a potential tumor suppressor inhibiting epithelial-to-mesenchymal transition but frequently silenced in prostate cancer by promoter methylation.
Tan W; Wang L; Ma Q; Qi M; Lu N; Zhang L; Han B
Prostate; 2015 Aug; 75(11):1197-205. PubMed ID: 25877612
[TBL] [Abstract][Full Text] [Related]
27. Overexpression of OCT4 induced by modulation of histone marks plays crucial role in breast cancer progression.
Kar S; Patra SK
Gene; 2018 Feb; 643():35-45. PubMed ID: 29203199
[TBL] [Abstract][Full Text] [Related]
28. Influence of neuroendocrine tumor cells on proliferation in prostatic carcinoma.
Grobholz R; Griebe M; Sauer CG; Michel MS; Trojan L; Bleyl U
Hum Pathol; 2005 May; 36(5):562-70. PubMed ID: 15948124
[TBL] [Abstract][Full Text] [Related]
29. Impairment of IGF2 gene expression in prostate cancer is triggered by epigenetic dysregulation of IGF2-DMR0 and its interaction with KLF4.
Schagdarsurengin U; Lammert A; Schunk N; Sheridan D; Gattenloehner S; Steger K; Wagenlehner F; Dansranjavin T
Cell Commun Signal; 2017 Oct; 15(1):40. PubMed ID: 29017567
[TBL] [Abstract][Full Text] [Related]
30. Gene profiling and pathway analysis of neuroendocrine transdifferentiated prostate cancer cells.
Mori R; Xiong S; Wang Q; Tarabolous C; Shimada H; Panteris E; Danenberg KD; Danenberg PV; Pinski JK
Prostate; 2009 Jan; 69(1):12-23. PubMed ID: 18814146
[TBL] [Abstract][Full Text] [Related]
31. Exposure of Human Prostaspheres to Bisphenol A Epigenetically Regulates SNORD Family Noncoding RNAs via Histone Modification.
Ho SM; Cheong A; Lam HM; Hu WY; Shi GB; Zhu X; Chen J; Zhang X; Medvedovic M; Leung YK; Prins GS
Endocrinology; 2015 Nov; 156(11):3984-95. PubMed ID: 26248216
[TBL] [Abstract][Full Text] [Related]
32. Secretagogin is a new neuroendocrine marker in the human prostate.
Adolf K; Wagner L; Bergh A; Stattin P; Ottosen P; Borre M; Birkenkamp-Demtröder K; Orntoft TF; Tørring N
Prostate; 2007 Apr; 67(5):472-84. PubMed ID: 17285592
[TBL] [Abstract][Full Text] [Related]
33. Deregulated expression of selected histone methylases and demethylases in prostate carcinoma.
Vieira FQ; Costa-Pinheiro P; Ramalho-Carvalho J; Pereira A; Menezes FD; Antunes L; Carneiro I; Oliveira J; Henrique R; Jerónimo C
Endocr Relat Cancer; 2014 Feb; 21(1):51-61. PubMed ID: 24200674
[TBL] [Abstract][Full Text] [Related]
34. Oxidative stress-induced epigenetic changes associated with malignant transformation of human kidney epithelial cells.
Mahalingaiah PK; Ponnusamy L; Singh KP
Oncotarget; 2017 Feb; 8(7):11127-11143. PubMed ID: 27655674
[TBL] [Abstract][Full Text] [Related]
35. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.
Masumori N; Thomas TZ; Chaurand P; Case T; Paul M; Kasper S; Caprioli RM; Tsukamoto T; Shappell SB; Matusik RJ
Cancer Res; 2001 Mar; 61(5):2239-49. PubMed ID: 11280793
[TBL] [Abstract][Full Text] [Related]
36. The association between histone 3 lysine 27 trimethylation (H3K27me3) and prostate cancer: relationship with clinicopathological parameters.
Ngollo M; Lebert A; Dagdemir A; Judes G; Karsli-Ceppioglu S; Daures M; Kemeny JL; Penault-Llorca F; Boiteux JP; Bignon YJ; Guy L; Bernard-Gallon D
BMC Cancer; 2014 Dec; 14():994. PubMed ID: 25535400
[TBL] [Abstract][Full Text] [Related]
37. Bivalent Histone Codes on WNT5A during Odontogenic Differentiation.
Zhou Y; Zheng L; Li F; Wan M; Fan Y; Zhou X; Du W; Pi C; Cui D; Zhang B; Sun J; Zhou X
J Dent Res; 2018 Jan; 97(1):99-107. PubMed ID: 28880717
[TBL] [Abstract][Full Text] [Related]
38. SFRP1 repression in prostate cancer is triggered by two different epigenetic mechanisms.
García-Tobilla P; Solórzano SR; Salido-Guadarrama I; González-Covarrubias V; Morales-Montor G; Díaz-Otañez CE; Rodríguez-Dorantes M
Gene; 2016 Nov; 593(2):292-301. PubMed ID: 27570179
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic disruption of miR-130a promotes prostate cancer by targeting SEC23B and DEPDC1.
Ramalho-Carvalho J; Martins JB; Cekaite L; Sveen A; Torres-Ferreira J; Graça I; Costa-Pinheiro P; Eilertsen IA; Antunes L; Oliveira J; Lothe RA; Henrique R; Jerónimo C
Cancer Lett; 2017 Jan; 385():150-159. PubMed ID: 27984115
[TBL] [Abstract][Full Text] [Related]
40. FOXA1 inhibits prostate cancer neuroendocrine differentiation.
Kim J; Jin H; Zhao JC; Yang YA; Li Y; Yang X; Dong X; Yu J
Oncogene; 2017 Jul; 36(28):4072-4080. PubMed ID: 28319070
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
